Indications |
Oral Ascariasis Adult: 100 mg bid for 3 consecutive days. Alternatively, 500 mg as a single dose. A 2nd course may be given if patient is not cured within 3-4 wk. Child: >1 yr: 100 mg bid for 3 consecutive days. Alternatively, 500 mg as a single dose. A 2nd course may be given if patient is not cured within 3-4 wk. Hepatic impairment: Dose reduction may be required. Oral Trichuriasis Adult: 100 mg bid for 3 consecutive days. Alternatively, 500 mg as a single dose. A 2nd course may be given if patient is not cured within 3-4 wk. Child: >1 yr: 100 mg bid for 3 consecutive days. Alternatively, 500 mg as a single dose. A 2nd course may be given if patient is not cured within 3-4 wk. Hepatic impairment: Dose reduction may be required. Oral Hookworm infections Adult: 100 mg bid for 3 consecutive days. Alternatively, 500 mg as a single dose. A 2nd course may be given if patient is not cured within 3-4 wk. Child: >1 yr: 100 mg bid for 3 consecutive days. Alternatively, 500 mg as a single dose. A 2nd course may be given if patient is not cured within 3-4 wk. Hepatic impairment: Dose reduction may be required. Oral Enterobiasis Adult: 100 mg as a single dose; may repeat if necessary 2-3 wk after initial treatment. Child: >2 yr: 100 mg as a single dose; may repeat if necessary 2-3 wk after initial treatment. Hepatic impairment: Dose reduction may be required. Oral Capillariasis Adult: 200 mg bid for 20 days. Child: >2 yr: 200 mg bid for 20 days. Hepatic impairment: Dose reduction may be required. Oral Filariasis Adult: Caused by Mansonella perstans: 100 mg bid for 30 days; caused by Onchocerca volvulus: 1 g bid for 28 days. Child: >2 yr: 100 mg bid for 30 days. Hepatic impairment: Dose reduction may be required. Oral Toxocariasis Adult: 100-200 mg bid for 5 days; may continue for up to 20 days. Child: >2 yr: 100-200 mg bid for 5-20 days. Hepatic impairment: Dose reduction may be required. Oral Trichinellosis Adult: Caused by Trichinella spiralis: 200-400 mg tid for 3 days followed by 400-500 mg tid for 10 days. Child: >2 yr: 200-400 mg tid for 3 days followed by 500 mg tid for 10 days. Hepatic impairment: Dose reduction may be required. Oral Trichostrongyliasis Adult: Caused by Trichostronglus: 100 mg bid for 3 consecutive days. Child: >2 yr: 100 mg bid for 3 consecutive days. Hepatic impairment: Dose reduction may be required. Oral Dracunculiasis Adult: Caused by Dracunculus medinensis: 400-800 mg daily for 6 days. |
Contraindications |
Hypersensitivity. Infants and children <2 yr. |
Warnings / Precautions |
Monitor blood counts and hepatic function especially in patients receiving high doses. Pregnancy and lactation. |
Adverse Reactions |
Transient diarrhoea, abdominal pain, nausea, vomiting, headache, tinnitus, numbness, fever and dizziness. Potentially Fatal: Myelosuppression (high doses). |
Overdose Reactions |
Symptoms: Abdominal pain, altered mental status. Management: Supportive. |
Drug Interactions |
Reduced plasma levels with enzyme inducers e.g. phenytoin, carbamazepine. Increased plasma levels with cimetidine. See Below for More mebendazole Drug Interactions |
Food Interactions |
Fatty food increases absorption. |
Mechanism of Actions |
Mebendazole acts by destroying the cytoplasmic microtubules in the worm's intestinal cells. This blocks the uptake of glucose and other nutrients resulting in death of the helminth. Absorption: Poorly absorbed from the GI tract. Distribution: Highly protein-bound. Metabolism: Extensively hepatic; undergoes 1st-pass elimination. Excretion: Mainly via faeces (as unchanged drug and metabolites); via urine (2%, as unchanged drug and metabolites). |
Administration |
May be taken with or without food. |
ATC Classification |
P02CA01 - mebendazole ; Belongs to the class of benzimidazole derivative agents. Used as antinematodal. |
Available As |
|
Mebendazole
Post Review about Mebendazole Click here to cancel reply.
Mebendazole Containing Brands
Mebendazole is used in following diseases
Drug - Drug Interactions of Mebendazole
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.